Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

Vaccine

Volumn 27, Issue 17, 2009, Pages 2394-2401

  Jansen, Angelique G S C ^a   Rodenburg, Gerwin D ^a   de Greeff, Sabine C ^b   Hak, Eelko ^a,c,f   Veenhoven, Reinier H ^d   Spanjaard, Lodewijk ^e   Schouls, Leo M ^b   Sanders, Elisabeth A M ^a   van der Ende, Arie ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Infection and Immunology   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Disease course; Epidemiology; Invasive pneumococcal disease; Outcome; Serotype distribution

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTEREMIA; CHILD; DRUG EFFICACY; HEALTH SURVEY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MAJOR CLINICAL STUDY; NETHERLANDS; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; NETHERLANDS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES;

EID: 62249197518     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.127     Document Type: Article

References (30)

1. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
2. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
3. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Hadler J., Reingold A., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295 14 (2006) 1668-1674
4. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 9 (2007) 1346-1354
5. Käyhty H., Auranen K., Nohynek H., Dagan R., and Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 5 5 (2006) 651-668
6. Lipsitch M., O'Neill K., Cordy D., Bugalter B., Trzcinski M., Thompson C.M., et al. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis 196 8 (2007) 1221-1227
7. Moore M.R., and Whitney C.G. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?. Clin Infect Dis 46 2 (2008) 183-185
8. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A.L., Hadler J., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 144 1 (2006) 1-9
9. Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial meningitis in the Netherlands. Annual report 2006. University of Amsterdam, Amsterdam, the Netherlands; 2007.
10. de Greeff S.C., Sanders E.A., de Melker H.E., van der Ende A., Vermeer P.E., and Schouls L.M. Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk. Ned Tijschr Geneeskd 151 26 (2007) 1454-1457 [Dutch]
11. Hausdorff W.P. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr 161 Suppl. 2 (2002) S135-S139
12. Jefferson T., Ferroni E., Curtale F., Rossi P.G., and Borgia P. Streptococcus pneumoniae in Western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis 6 7 (2006) 405-410
13. Rüggeberg J.U., Ketteler K., MacKenzie C.R., von Kries R., Reinert R.R., and Schroten H. Blood culture sampling rates at a German pediatric University hospital and incidence of invasive pneumococcal disease. Infection 32 2 (2004) 78-81
14. Kaplan S.L., Mason E.O., Barson W.J., Wald E.R., Arditi M., Tan T.Q., et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 102 3 Pt 1 (1998) 538-545
15. Kaplan S.L., Mason E.O., Wald E.R., Tan T.Q., Schutze G.E., Bradley J.S., et al. Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J 21 2 (2002) 141-147
16. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998. Opportunities for prevention in the conjugate vaccine era. JAMA 285 13 (2001) 1729-1735
17. Mirzanejad Y., Roman S., Talbot J., and Nicolle L. Pneumococcal bacteremia in two tertiary care hospitals in Winnipeg, Canada. Pneumococcal bacteremia study group. Chest 109 1 (1996) 173-178
18. Reinert R.R., Haupts S., van der Linden M., Heeg C., Cil M.Y., Al-Lahham A., et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect 11 12 (2005) 985-991
19. Kyaw M.H., Christie P., Clarke S.C., Mooney J.D., Ahmed S., Jones I.G., et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 37 10 (2003) 1283-1291
20. Sleeman K., Knox K., George R., Miller E., Waight P., Griffiths D., et al. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183 2 (2001) 239-246
21. Gjini A., Stuart J.M., George R.C., Nichols T., and Heyderman R.S. Capture-recapture analysis and pneumococcal meningitis estimates in England. Emerg Infect Dis 10 1 (2004) 87-93
22. Pagliano P., Fusco U., Attanasio V., Rossi M., Pantosti A., Conte M., et al. Pneumococcal meningitis in childhood: a longitudinal prospective study. FEMS Immunol Med Microbiol 51 3 (2007) 488-495
23. Arditi M., Mason E.O., Bradley J.S., Tan T.Q., Barson W.J., Schutze G.E., et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 102 5 (1998) 1087-1097
24. Compass National Health. Bilthoven, The Netherlands: National Institute for Public Health and the Environment, http://www.nationaalkompas.nl.
25. Mahon B.E., Ehrenstein V., Nørgaard M., Pedersen L., Rothman K.J., and Sørensen H.T. Perinatal risk factors for hospitalization for pneumococcal disease in childhood: a population-based cohort study. Pediatrics 119 4 (2007) e804-e812
26. Kyaw M.H., Rose Jr. C.E., Fry A.M., Singleton J.A., Moore Z., Zell E.R., et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192 3 (2005) 377-386
27. Chi R.C., Jackson L.A., and Neuzil K.M. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. J Am Geriatr Soc 54 1 (2006) 115-120
28. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, Part I. Clin Infect Dis 30 1 (2000) 100-121
29. Ihekweazu C.A., Dance D.A., Pebody R., George R.C., Smith M.D., Waight P., et al. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol Infect 136 8 (2008) 1096-1102
30. Scott D.A., Komjathy S.F., Hu B.T., Baker S., Supan L.A., Monahan C.A., et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25 33 (2007) 6164-6166